자궁경부암 시장 - 시장 인사이트, 역학, 시장 예측(2034년)

Key Highlights:

• The US accounted for the largest market size of cervical cancer, i.e., nearly USD 530 million in 2023.
• Cervical cancer is most often diagnosed between the ages of 35 and 44. The average age of diagnosis in the US is 50. Over 20% of cervical cancers are diagnosed after age 65. It is rare for people younger than 20 to develop cervical cancer.
• Over the past two decades, the majority of countries in the 7MM have experienced a decrease in cervical cancer cases. In the United States, incidence rates showed a decline from the mid-1970s to the mid-2000s, attributed in part to increased screening efforts. However, an analysis of SEER data revealed a rise in cases in 2021 following the COVID-19 pandemic, which later returned to a declining trend. In the EU4 and the UK, most nations observed a gradual decrease, though Spain and the UK saw relatively stable numbers over the past decade. Despite being a latecomer to HPV vaccination, Japan reported fewer cases in 2023 compared to 2020. While vaccination resumed in November 2021, it remains to be seen whether a significant decline in numbers will occur in the future.
• Immunotherapy holds promise for establishing new standards in cervical cancer treatment. Biomarkers to evaluate immunotherapy response will likely play a crucial role in identifying suitable candidates.
• KEYTRUDA (pembrolizumab) approval marks a groundbreaking development, positioning it as the inaugural immune checkpoint inhibitor sanctioned for the treatment of cervical cancer.
• In 2023, the total incident cases of cervical cancer were nearly 40,600 in the 7MM, which is expected to decrease by 2034. The US, in 2023, accounted for the highest cases.
• In February 2024, Pfizer and Genmab announced that the European Medicines Agency (EMA) validated tisotumab vedotin's marketing authorization application for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after first-line therapy.
• In September 2023, Nykode Therapeutics announced the US FDA approval of its Investigational New Drug (IND) application for the Phase II clinical trial of VB10.16, for HPV16-positive cancers, in combination with Roche's PD-L1 inhibitor atezolizumab in patients with HPV16-positive, PD-L1-positive, recurrent or metastatic cervical cancer.

DelveInsight's "Cervical Cancer-Market Insight, Epidemiology and Market Forecast-2034" report delivers an in-depth understanding of cervical cancer, historical and forecasted epidemiology as well as the cervical cancer market trends in the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan.

The cervical cancer market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM cervical cancer market size from 2020 to 2034. The report also covers current cervical cancer treatment practices/algorithms, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2020-2034

Cervical Cancer Disease Understanding and Treatment Algorithm

Cervical Cancer Overview

Cervical cancer starts in the cells of the cervix. The cervix is the lower, narrow end of the uterus (womb); the cervix connects the uterus to the vagina (birth canal). Cervical cancer usually develops slowly over time. At first, the changes in a cell are abnormal, not cancerous, and are sometimes called "atypical cells." Researchers believe that some of these abnormal changes are the first step in a series of slow changes that can lead to cancer. Before cancer appears in the cervix, the cells of the cervix go through dysplasia, and abnormal cells begin to appear in the cervical tissue. Over time, if not destroyed or removed, the abnormal cells may become cancer cells and start to grow and spread more deeply into the cervix and to surrounding areas.

Cervical Cancer Diagnosis

Diagnosis of cervical cancer typically involves several steps. Initially, a thorough medical history is taken, encompassing any pertinent symptoms and risk factors. This is followed by a physical examination, including a pelvic exam, to detect any abnormalities in the cervix. A Pap smear, also known as a Pap test, is then conducted to screen for abnormal cervical cells. This involves collecting cells from the cervix and examining them under a microscope. Additionally, an HPV test may be performed concurrently to check for the presence of the human papillomavirus (HPV), a common cause of cervical cancer. Depending on the results of these tests, further diagnostic procedures such as colposcopy, biopsy, or imaging studies may be necessary to confirm the presence of cervical cancer and determine its extent.

Cervical Cancer Treatment

Treatment for cervical cancer varies depending on factors like the cancer's stage, the patient's health, and their preferences. Typically, options include surgery, radiation therapy, chemotherapy, targeted therapy, or a combination. Surgical interventions may entail removing cancerous tissue or performing procedures like hysterectomy for advanced cases. Immunotherapy is another option, leveraging the body's immune system to fight cancer cells.

Further details are provided in the report...

Cervical Cancer Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Cases of Cervical Cancer, Total Cervical Cancer Cases by histology, Stage-specific Cases of Cervical Cancer, and Age-specific Cases of Cervical Cancer in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan from 2020 to 2034.

• The total incident cases of cervical cancer in the 7MM comprised 40,600 in 2023 and are projected to decrease during the forecast period.
• The US contributed to the largest incident population of cervical cancer, accounting for nearly 34% of the 7MM in 2023.
• Among the total cervical cancer cases by histology, the cases of squamous carcinoma comprised nearly 9,000 cases in 2023 in the US.
• Among the stage-specific cases of cervical cancer, Stage IB comprised the highest number of cases, followed by IVB in the US in 2023.
• Among EU4 and the UK, Germany accounted for the highest number of cervical cancer cases, followed by the UK, whereas Spain accounted for the lowest cases in 2023.

Cervical Cancer Drug Chapters

The drug chapter segment of the cervical cancer report encloses a detailed analysis of cervical cancer marketed and emerging (Phase-III and Phase II and Phase I/II) pipeline drugs. It also helps to understand the cervical cancer clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Marketed Drugs

KEYTRUDA (pembrolizumab): Merck Sharp & Dohme

Pembrolizumab is the active ingredient of KEYTRUDA, a humanized monoclonal antibody that binds to the programmed cell death-1 (PD-1) receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including antitumor immune response. Binding the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor on T cells inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors, and signaling through this pathway can inhibit active T-cell immune surveillance of tumors. It has been approved by the US FDA three times, with the latest approval being in January 2024. Merck announced that the US FDA has approved KEYTRUDA combination with chemoradiotherapy (CRT) for the treatment of patients with FIGO (International Federation of Gynecology and Obstetrics) 2014 Stage III-IVA cervical cancer. In April 2022, Merck announced that the European Commission approved KEYTRUDA in combination with chemotherapy, with or without bevacizumab, for the treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumors express PD-L1. In September 2022, Merck announced that KEYTRUDA in combination with chemotherapy, with or without bevacizumab, received approvals from Japan's Ministry of Health, Labor and Welfare (MHLW) for the treatment of patients with advanced or recurrent cervical cancer with no prior chemotherapy who are not amenable to curative treatment.

TIVDAK (Tisotumab vedotin-tftv): Genmab/Pfizer

TIVDAK (tisotumab vedotin-tftv) is an antibody-drug conjugate (ADC) composed of Genmab's human monoclonal antibody directed to tissue factor (TF) and Pfizer's ADC technology that utilizes a protease-cleavable linker that covalently attaches the microtubule-disrupting agent monomethyl auristatin E (MMAE) to the antibody. It is co-developed globally and copromoted in the US in collaboration with Pfizer. In September 2021, Genmab and Seagen announced that the US FDA granted accelerated approval to TIVDAK for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. In February 2024, Pfizer and Genmab announced that the European Medicines Agency had validated tisotumab vedotin's marketing authorization application for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after first-line therapy.

Note: Detailed marketed therapies assessment will be provided in the final report.

Emerging Drugs

Volrustomig: AstraZeneca

Volrustomig is a bispecific monoclonal antibody that is administered through an intravenous route. It acts by targeting programmed cell death protein 1 (PD-1) and cytotoxic T lymphocyte Protein 4 (CTLA4). Currently, the company is conducting a Phase III (NCT06079671) eVOLVE-Cervical/eVOLVECervical study to explore the efficacy and safety of volrustomig in women with high-risk locally advanced cervical cancer (FIGO 2018 stage IIIC to IVA cervical cancer with lymph node involvement) who have not progressed following platinum-based CCRT. The company anticipates the first estimated filing acceptance after 2025.

PRGN-2009: Precigen

PRGN-2009 is a novel, replication-incompetent gorilla adenovirus targeting HPV-associated cancers. It can be administered repeatedly, leading to the enhancement of T cells without increasing neutralizing antibodies. PRGN-2009 leverages Precigen's UltraVector and AdenoVerse platforms to optimize HPV 16/18 antigen design and delivery using gorilla adenovector with a large payload capacity and the ability for repeat administration. Recently, in May 2023, IND for a Phase II trial of PRGN-2009 was cleared by the FDA, and the company has initiated a Phase II (NCT06157151) trial to evaluate the efficacy and safety of PRGN-2009 in combination with pembrolizumab compared to pembrolizumab alone in patients with pembrolizumab-resistant recurrent or metastatic cervical cancer. In addition, the company completed a Phase I (NCT04432597) study and presented positive Phase 1I clinical data from the monotherapy and combination therapy arms in patients with recurrent or metastatic HPV-associated cancers at the 2023 ASCO annual meeting.

Drug Class Insights

Currently, chemotherapy and immunotherapy are two promising treatment options for cervical cancer patients. The landscape has evolved with the introduction of immune checkpoint inhibitors, HER2-tyrosine kinase inhibitors, HER2- -antagonists with DNA topoisomerase I inhibitors, and other emerging drug classes reshaping the treatment paradigm of cervical cancer. Pembrolizumab's approval marks a groundbreaking development, positioning it as the inaugural immune checkpoint inhibitor sanctioned for the treatment of cervical cancer. Genmab/Pfizer's TIVDAK, an antibody-drug conjugate also presents a promising option for second-line treatment, its potential could be further enhanced when combined with PD-L1 inhibitors in the frontline setting. LIBTAYO, a fully human monoclonal antibody targeting the PD-1 immune checkpoint receptor is another therapy that became the first single-agent immunotherapy in Japan.

Cervical Cancer Market Outlook

A robust pipeline with a novel mechanism of action and increasing incidence are major market drivers of the cervical cancer market. Additionally, the cervical cancer pipeline is also expected to change the current dynamics of the market, which presently comprises biologics and molecules with new mechanisms of action.

Women with unresectable, locally advanced cervical cancer often undergo treatment with chemoradiotherapy (CRT), but this approach is linked to late toxicities that adversely affect quality of life. Moreover, recurrence following CRT carries a grim prognosis. In recent years, the standard first-line treatment for persistent, recurrent, or metastatic cervical cancer has evolved. While chemotherapy doublets, typically platinum-based, have long been the go-to option, the current preferred regimen involves augmenting cisplatin-paclitaxel with bevacizumab, a VEGF monoclonal antibody. In 2014, the FDA approved Genentech/Roche's AVASTIN (bevacizumab) for use in combination with chemotherapy in women with advanced cervical cancer. This approval marked a significant milestone, as it was the first drug to gain FDA approval for late-stage cervical cancer patients since the approval of topotecan with cisplatin in 2006. Over the past decade, biosimilars have emerged as a transformative force within the healthcare industry, offering the potential to foster a more sustainable healthcare system. In September 2017, the FDA achieved a historic milestone by granting approval to Amgen's MVASI, marking the first biosimilar for cancer therapy authorized for use in the United States as a counterpart to Roche's AVASTIN. AVASTIN had been shielded by patents until 2019. Treatment innovations, such as targeted therapies and immunotherapies, are reshaping cervical cancer management, with drugs like tisotumab vedotin marking a breakthrough. Ongoing research drives advancements in therapies and diagnostics, emphasizing precision medicine. Key players like AstraZeneca and Roche, Precigen, and Nykode Therapeutics are driving progress in the cervical cancer treatment landscape. Overall, the cervical cancer market is further expected to increase in the forecast period (2024-2034).

• The total market size of cervical cancer in the 7MM was approximately USD 930 million in 2023 and is projected to increase during the forecast period.
• Among EU4 and the UK, Germany accounted for the maximum market size in 2023, while Italy occupied the bottom of the ladder.
• Among the therapies, KEYTRUDA is expected to generate the highest revenue in the 7MM by 2034.
• TIVDAK, as the only ADC approved for cervical cancer, carries a boxed warning for ocular side effects. However, Seagen/Genmab's TIVDAK demonstrates the potential for advancement into earlier lines of treatment, akin to Merck's Keytruda, especially for patients whose tumors express the PD-L1 biomarker.
• Key players such as AstraZeneca, Roche, Precigen, and Nykode Therapeutics are leading advancements in the treatment of cervical cancer.

Cervical Cancer Drugs Uptake

This section focuses on the rate of uptake of the potential drugs expected to be launched in the market during the study period. The analysis covers cervical cancer market uptake by drugs; patient uptake by therapies; and sales of each drug. Iovance's one-time TIL-based autologous cell therapy is expected to perform better than the approved CAR-T (used in Hematological malignancies) as TILs are directly extracted from tumors rather than blood.

Cervical Cancer Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I/II stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers detailed information on collaborations, acquisitions and mergers, licensing, and patent details for cervical cancer emerging therapies.

KOL- Views

To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Some of the leaders like MD, Professor and Vice Chair Department of Critical Care Medicine and Director, PhD, and others. Their opinion helps to understand and validate current and emerging therapies and treatment patterns or cervical cancer market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Delveinsight's analysts connected with 30+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as the Center for Cervical Dysplasia, Department of Gynecological Oncology, Division of Obstetrics and Gynecology, etc., were contacted. Their opinion helps understand and validate cervical cancer epidemiology and market trends.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Analyst views. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

The analyst analyzes multiple emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial's primary and secondary outcome measures are evaluated.

Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials.

Market Access and Reimbursement

According to the Centers for Disease Control and Prevention, if cancer diagnosis and treatment were divided into phases of care, then the initial phase would be the first year after a diagnosis, the end-of-life phase would be the year before death from cancer, and the continuing care phase would be the time in between these two phases. The average per-patient costs for medical services were highest for the end-of-life phase, which is nearly USD 97,000, followed by the initial care phase with nearly USD 60,000, and the continuing care phase with nearly USD 4,000. The average per-patient costs for oral prescription drugs were USD 500 for the last year of life. The list price for each indicated dose of KEYTRUDA, when given every 3 weeks, is USD 11,115.04. The list price for each indicated dose of KEYTRUDA, when given every 6 weeks, is USD 22,230.08. Most people will not pay the list price, although it may have an impact on the patient's out-of-pocket costs. The amount that the patient will pay will depend on many factors, including the patient's insurance situation.

Further details will be provided in the final report.

Scope of the Report:

• The report covers a descriptive overview of cervical cancer, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into cervical cancer epidemiology and treatment.
• Additionally, an all-inclusive account of both the current and emerging therapies for cervical cancer is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of the cervical cancer market; historical and forecasted is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM cervical cancer market.

Cervical Cancer Report Insights

Cervical Cancer Report Insights

• Patient Population
• Therapeutic Approaches
• Cervical Cancer Pipeline Analysis
• Cervical Cancer Market Size and Trends
• Market Opportunities
• Impact of Upcoming Therapies

Cervical Cancer Report Key Strengths

• Eleven Years Forecast
• 7MM Coverage
• Cervical Cancer Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Cervical Cancer Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)

FAQs

• What was the cervical cancer market share (%) distribution in 2020 and what it would look like in 2034?
• What would be the cervical cancer total market size as well as market size by therapies across the 7MM during the study period (2020-2034)?
• What are the key findings about the market across the 7MM and which country will have the largest cervical cancer market size during the study period (2020-2034)?
• At what CAGR, the cervical cancer market is expected to grow at the 7MM level during the study period (2020-2034)?
• What would be the cervical cancer market outlook across the 7MM during the study period (2020-2034)?
• What are the disease risk, burden, and unmet needs of cervical cancer?
• What is the historical cervical cancer patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
• What would be the forecasted sales of KEYTRUDA and TIVDAK in cervical cancer in the 7MM?
• What will be the growth opportunities across the 7MM concerning the patient population of cervical cancer?
• Out of the above-mentioned countries, which country would have the highest incident population of cervical cancer during the study period (2020-2034)?
• At what CAGR the population is expected to decline across the 7MM during the study period (2020-2034)?
• Which emerging therapy captures the highest revenue for 2L treatment of cervical cancer in the US?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and licensing activities related to cervical cancer therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
• What are the key designations that have been granted for the emerging therapies for cervical cancer?

Reasons to buy:

• The report will help in developing business strategies by understanding trends shaping and driving cervical cancer.
• To understand the future market competition in the cervical cancer market and Insightful review of the SWOT analysis of cervical cancer.
• Organize sales and marketing efforts by identifying the best opportunities for cervical cancer in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for the cervical cancer market.
• To understand the future market competition in the cervical cancer market.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary of Cervical Cancer

4. Cervical Cancer Market Overview at a Glance

• 4.1. Market Share by Therapies (%) Distribution of Cervical Cancer in 2020 in the 7MM
• 4.2. Market Share by Therapies (%) Distribution of Cervical Cancer in 2034 in the 7MM

5. Key Events

6. Epidemiology and Market Forecast Methodology

7. Disease Background and Overview

• 7.1. Introduction
• 7.2. Symptoms
• 7.3. Types
• 7.4. Stages
  • 7.4.1. Stage I Cervical Cancer
  • 7.4.2. Stage II Cervical Cancer
  • 7.4.3. Stage III Cervical Cancer
  • 7.4.4. Stage IV Cervical Cancer
• 7.5. Risk Factors
  • 7.5.1. Weakened Immune System
  • 7.5.2. Sexually Transmitted Infections (STIs)
  • 7.5.3. Human Immunodeficiency Virus (HIV)
  • 7.5.4. Oral Contraceptive Pills
• 7.6. Etiology
• 7.7. Pathophysiology
  • 7.7.1. HPV Oncogenesis
• 7.8. Biomarkers
• 7.9. Diagnosis
• 7.1. Prevention

8. Treatment

• 8.1. Surgical Treatment
• 8.2. Radiation
• 8.3. Chemotherapy
• 8.4. Immunotherapy

9. Guidelines

• 9.1. Treatment Guideline
  • 9.1.1. NCCN Guideline (2024)
  • 9.1.2. Triage Algorithm for Women Aged 30-65 years to whom an HPV Test has Been Proposed for Primary Cervical Cancer Screening
  • 9.1.3. Japan Society of Gynecologic Guidelines
• 9.2. Guidelines for Screening
  • 9.2.1. American Society of Clinical Oncology (ASCO)
  • 9.2.2. American Cancer Society (ACS) Guidelines for the Prevention and Early Detection of Cervical Cancer
  • 9.2.3. American College of Obstetricians and Gynecologists (ACOG) Guidelines
  • 9.2.4. Screening Recommendations by the USPSTF
  • 9.2.5. National Breast and Cervical Cancer Early Detection Program (NBCCEDP)
  • 9.2.6. Screening Guideline in Germany (2023)
  • 9.2.7. Screening Guideline in France (2023)
  • 9.2.8. Screening Guideline in Italy (2023)
  • 9.2.9. Screening Program in UK (2023)
  • 9.2.10. Screening Guideline in Japan

10. Epidemiology and Patient Population

• 10.1. Key Findings
• 10.2. Assumptions and Rationale
• 10.3. Total Incident Cases of Cervical Cancer in the 7MM
• 10.4. The United States
  • 10.4.1. Total Incident Cases of Cervical Cancer in the United States
  • 10.4.2. Histology Type-specific Cases of Cervical Cancer in the United States
  • 10.4.3. Stage-specific Cases of Cervical Cancer in the United States
  • 10.4.4. Age-specific Cases of Cervical Cancer in the United States
• 10.5. EU4 and the UK
  • 10.5.1. Total Incident Cases of Cervical Cancer in EU4 and the UK
  • 10.5.2. Histology Type-specific Cases of Cervical Cancer in EU4 and the UK
  • 10.5.3. Stage-specific Cases of Cervical Cancer in EU4 and the UK
  • 10.5.4. Age-specific Cases of Cervical Cancer in EU4 and the UK
• 10.6. Japan
  • 10.6.1. Total Incident Cases of Cervical Cancer in Japan
  • 10.6.2. Histology Type-specific Cases of Cervical Cancer in Japan
  • 10.6.3. Stage-specific Incident Cases of Cervical Cancer in Japan
  • 10.6.4. Age-specific Cases of Cervical Cancer in Japan

11. Patient Journey

• 11.1. Description

12. Marketed Drugs

• 12.1. Key Competitors
• 12.2. KEYTRUDA (pembrolizumab): Merck Sharp & Dohme
  • 12.2.1. Product Description
  • 12.2.2. Regulatory Milestones
  • 12.2.3. Other Developmental Activities
  • 12.2.4. Clinical Development
    • 12.2.4.1. Clinical Trial Information
  • 12.2.5. Safety and Efficacy
  • 12.2.6. Product Profile
• 12.3. TIVDAK (Tisotumab vedotin-tftv): Genmab/Pfizer
  • 12.3.1. Product Description
  • 12.3.2. Regulatory Milestones
  • 12.3.3. Other Developmental Activities
  • 12.3.4. Clinical Development
    • 12.3.4.1. Clinical Trial Information
  • 12.3.5. Safety and Efficacy
  • 12.3.6. Product Profile
• 12.4. LIBTAYO (cemiplimab): Regeneron/Medison Pharma
  • 12.4.1. Product Description
  • 12.4.2. Regulatory Milestones
  • 12.4.3. Other Developmental Activities
  • 12.4.4. Clinical Development
    • 12.4.4.1. Clinical Trial Information
  • 12.4.5. Safety and Efficacy
  • 12.4.6. Product Profile
• 12.5. AVASTIN (bevacizumab): Genentech/Roche
  • 12.5.1. Product Description
  • 12.5.2. Regulatory Milestones
  • 12.5.3. Other Developmental Activities
  • 12.5.4. Safety and Efficacy
  • 12.5.5. Product Profile

13. Emerging Drugs

• 13.1. Key Competitors
• 13.2. TECENTRIQ (atezolizumab): Roche
  • 13.2.1. Product Description
  • 13.2.2. Clinical Development
    • 13.2.2.1. Clinical Trial Information
  • 13.2.3. Safety and Efficacy
• 13.3. Volrustomig: AstraZeneca
  • 13.3.1. Product Description
  • 13.3.2. Other Developmental Activities
  • 13.3.3. Clinical Development
    • 13.3.3.1. Clinical Trials Information
• 13.4. PRGN-2009: Precigen
  • 13.4.1. Product Description
  • 13.4.2. Clinical Development
    • 13.4.2.1. Clinical Trials Information
  • 13.4.3. Safety and Efficacy
• 13.5. NERLYNX (neratinib): Puma Biotechnology
  • 13.5.1. Product Description
  • 13.5.2. Other Developmental Activities
  • 13.5.3. Clinical Development
    • 13.5.3.1. Clinical Trials Information
  • 13.5.4. Safety and Efficacy
• 13.6. Lifileucel (LN-145): Iovance Biotherapeutics
  • 13.6.1. Product Description
  • 13.6.2. Other Developmental Activities
  • 13.6.3. Clinical Development
    • 13.6.3.1. Clinical Trial Information
  • 13.6.4. Safety and Efficacy
• 13.7. VB10.16: Nykode Therapeutics/Roche
  • 13.7.1. Product Description
  • 13.7.2. Other Developmental Activities
  • 13.7.3. Clinical Development
    • 13.7.3.1. Clinical Trial Information
  • 13.7.4. Safety and Efficacy
• 13.8. ISA101b: ISA Pharmaceuticals/Regeneron
  • 13.8.1. Product Description
  • 13.8.2. Other Developmental Activities
  • 13.8.3. Clinical Development
    • 13.8.3.1. Clinical Trial Information
  • 13.8.4. Safety and Efficacy
• 13.9. ENHERTU (trastuzumab deruxtecan): Daiichi Sankyo/ AstraZeneca
  • 13.9.1. Product Description
  • 13.9.2. Other Developmental Activities
  • 13.9.3. Clinical Development
    • 13.9.3.1. Clinical Trial Information
  • 13.9.4. Safety and Efficacy
• 13.1. TG4001: Transgene
  • 13.10.1. Product Description
  • 13.10.2. Other Developmental Activities
  • 13.10.3. Clinical Development
    • 13.10.3.1. Clinical Trials Information
  • 13.10.4. Safety and Efficacy

14. Cervical Cancer: Market Analysis

• 14.1. Key Findings
• 14.2. Market Outlook
• 14.3. Conjoint Analysis
• 14.4. Key Market Forecast Assumptions
• 14.5. Total Market Size of Cervical Cancer in the 7MM
• 14.6. United States Market Size
  • 14.6.1. Total Market Size of Cervical Cancer in the United States
  • 14.6.2. Market Size of Cervical Cancer by Therapies in the United States
• 14.7. EU4 and the UK Market Size
  • 14.7.1. Total Market Size of Cervical Cancer in EU4 and the UK
  • 14.7.2. Market Size of Cervical Cancer by Therapies in EU4 and the UK
• 14.8. Japan Market Size
  • 14.8.1. Total Market Size of Cervical Cancer in Japan
  • 14.8.2. Market Size of Cervical Cancer by Therapies in Japan

15. Unmet Needs

16. SWOT Analysis

17. KOL Views

18. Market Access and Reimbursement

• 18.1. United States
  • 18.1.1. Centre for Medicare and Medicaid Services (CMS)
• 18.2. EU4 and the UK
  • 18.2.1. Germany
  • 18.2.2. France
  • 18.2.3. Italy
  • 18.2.4. Spain
  • 18.2.5. United Kingdom
• 18.3. Japan
  • 18.3.1. MHLW
• 18.4. Market Access and Reimbursement of Cervical Cancer
  • 18.4.1. KEYTRUDA (pembrolizumab)
  • 18.4.2. TIVDAK (Tisotumab vedotin-tftv): Genmab/Pfizer
  • 18.4.3. LIBTAYO (cemiplimab): Regeneron/Medison Pharma
  • 18.4.4. AVASTIN (bevacizumab): Genentech/Roche

19. Appendix

• 19.1. Bibliography
• 19.2. Report Methodology

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight